PL378762A1 - Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi - Google Patents

Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi

Info

Publication number
PL378762A1
PL378762A1 PL378762A PL37876204A PL378762A1 PL 378762 A1 PL378762 A1 PL 378762A1 PL 378762 A PL378762 A PL 378762A PL 37876204 A PL37876204 A PL 37876204A PL 378762 A1 PL378762 A1 PL 378762A1
Authority
PL
Poland
Prior art keywords
osteolyisis
excessive
treatment
indolinone compounds
indolinone
Prior art date
Application number
PL378762A
Other languages
English (en)
Polish (pl)
Inventor
Lesley Murray
Anne-Marie O'farrell
Tinya Abrams
Original Assignee
Sugen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen, Inc. filed Critical Sugen, Inc.
Publication of PL378762A1 publication Critical patent/PL378762A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL378762A 2003-02-24 2004-02-23 Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi PL378762A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44886103P 2003-02-24 2003-02-24
US10/780,917 US20040209937A1 (en) 2003-02-24 2004-02-19 Treatment of excessive osteolysis with indolinone compounds

Publications (1)

Publication Number Publication Date
PL378762A1 true PL378762A1 (pl) 2006-05-15

Family

ID=32930497

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378762A PL378762A1 (pl) 2003-02-24 2004-02-23 Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi

Country Status (11)

Country Link
US (1) US20040209937A1 (enExample)
EP (1) EP1599207A2 (enExample)
JP (1) JP2006518756A (enExample)
KR (1) KR20050113612A (enExample)
AU (1) AU2004216188A1 (enExample)
BR (1) BRPI0407793A (enExample)
CA (1) CA2516786A1 (enExample)
MX (1) MXPA05008961A (enExample)
NZ (1) NZ541825A (enExample)
PL (1) PL378762A1 (enExample)
WO (1) WO2004075775A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
WO2007034272A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
EP1977238B1 (en) * 2005-12-22 2016-09-28 Novartis AG Soluble human m-csf receptor and uses thereof
CN101367801B (zh) 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
CN102137842A (zh) * 2008-07-02 2011-07-27 基因里克斯(英国)有限公司 3-吡咯取代的2-吲哚酮衍生物的制备
CA2730079A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
WO2010011834A2 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CN102239163A (zh) * 2008-07-24 2011-11-09 特瓦制药工业有限公司 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US10898211B2 (en) 2015-01-14 2021-01-26 Crossroads Extremity Systems, Llc Opening and closing wedge osteotomy guide and method
US10292713B2 (en) 2015-01-28 2019-05-21 First Ray, LLC Freeform tri-planar osteotomy guide and method
US10376268B2 (en) 2015-02-19 2019-08-13 First Ray, LLC Indexed tri-planar osteotomy guide and method
EP3470394B1 (en) * 2016-06-09 2022-01-26 Yuki Gosei Kogyo Co., Ltd. Method for preparing 4-(piperidin-4-yl)morpholine
CN114513994B (zh) 2019-07-26 2025-08-01 汇聚义肢系统有限责任公司 骨复位引导系统和方法
US11779359B2 (en) 2020-02-19 2023-10-10 Crossroads Extremity Systems, Llc Systems and methods for Lapidus repair of bunions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1255752E (pt) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP1434774A1 (en) * 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals

Also Published As

Publication number Publication date
BRPI0407793A (pt) 2006-02-14
AU2004216188A1 (en) 2004-09-10
US20040209937A1 (en) 2004-10-21
NZ541825A (en) 2008-11-28
MXPA05008961A (es) 2005-11-04
WO2004075775A2 (en) 2004-09-10
KR20050113612A (ko) 2005-12-02
JP2006518756A (ja) 2006-08-17
EP1599207A2 (en) 2005-11-30
WO2004075775A3 (en) 2005-04-14
CA2516786A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
HU0302451D0 (en) New compounds with therapeutic effect
EP1689485A4 (en) CARDIOELECTROMAGNETIC TREATMENT
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
PL378762A1 (pl) Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi
GB0326486D0 (en) Combination treatment
GB0329874D0 (en) Compounds useful for the treatment of diseases
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
GB0305150D0 (en) Use of therapeutic compounds
GB0312407D0 (en) Treatment
GB0323258D0 (en) Therapeutic compounds
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
GB0400802D0 (en) Compounds for the treatment of disease
GB0426196D0 (en) Methods of treatment
EP1793813A4 (en) TREATMENT OF HYPERACTIVITY DISORDER WITH DEFICIT ATTENTION (ADHD)
IL180709A0 (en) Treatment of tumours
GB0327975D0 (en) Methods of treatment
GB0317500D0 (en) Treatment of bph
ZA200704046B (en) Treatment of burns
ZA200606780B (en) Compounds for the treatment of diseases
GB0317128D0 (en) Use of antitumoral compounds
GB0304021D0 (en) Treatment of hypertension
GB0325957D0 (en) The treatment of pain
HU0400952D0 (en) Treatment of anus-cancer
GB0322921D0 (en) Methods of treatment
GB0412262D0 (en) Use of compounds for the treatment of pain

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)